| Name | Title | Contact Details |
|---|---|---|
Alexander Clapp |
Senior Director, Finance and Data Analytics | Profile |
Steve DeSantis |
Chief Financial Officer | Profile |
Jade Frank |
Vice President, People Strategy | Profile |
John Ristuccia |
SVP, Global Client Services | Profile |
David Murray |
Chief Financial Officer | Profile |
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Novartis Vaccines and Diagnostics,Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Appello Pharmaceuticals is a Nashville, TN based preclinical-stage company focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson`s disease.
Ratiopharm Inc is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Triangle Compounding Pharmacy is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.